+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating disitamab vedotin alone or combined with pembrolizumab to treat urothelial cancer that expresses HER2. This study focuses on participants with locally advanced or metastatic urothelial cancer that cannot be removed by surgery. It aims to assess how well the drug works and to monitor the side effects experienced by participants. Participants receive disitamab vedotin intravenously every 2 weeks, either alone or with pembrolizumab given by intravenous infusion on Day 1 of each 6-week cycle. The study includes multiple cohorts receiving different combinations or monotherapy treatments. The treatment period and monitoring last approximately 2 years, with ongoing assessments of drug effects and safety. During the study, participants undergo regular evaluations including imaging scans to measure tumor response, laboratory tests, electrocardiograms to monitor heart function, and assessments of side effects. Researchers measure treatment response using established cancer evaluation criteria and track survival and disease control over about 3 years. Participants are closely monitored for adverse effects and blood levels of the drugs to understand how the treatments behave in the body.

Age: 18Years +All GendersPhase 2
221 locations
R

Actively Recruiting

Researchers are evaluating the effects of a medicine called BI 764198 in adults and adolescents with a kidney disease known as focal segmental glomerulosclerosis FSGS. This Phase 3 study aims to understand whether BI 764198 can help people with primary FSGS or genetic FSGS related to TRPC6 gene mutations. The trial is randomized, double-blind, and placebo-controlled, comparing BI 764198 tablets to placebo tablets. Participants take one tablet daily for up to two years alongside their usual FSGS treatments. They are randomly assigned to either the BI 764198 group or the placebo group, with equal chance to be in either. The study monitors participants over 104 weeks, collecting urine samples regularly to assess kidney function and compare results between groups. During the study, participants visit the study site about every three months for health assessments and safety monitoring. Researchers measure changes in urine protein-creatinine ratio and kidney filtration rate to evaluate treatment response. Additional questionnaires assess disease impact. The total participation time is up to two years, allowing long-term evaluation of the treatments effects and safety.

Age: 12Years +All GendersPhase 3
316 locations
E

Actively Recruiting

Researchers are studying the anti-cancer effects of inobrodib combined with pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma MM that no longer responds to existing treatments. This Phase II, open-label, multicenter study focuses on patients who have previously been treated with specific therapies including proteasome inhibitors, anti-CD38 monoclonal antibodies, pomalidomide, and bispecific T-cell engagers. The goal is to better understand the treatments activity and side effects in this patient group. Participants will receive 20 mg of inobrodib orally twice daily for 4 days followed by 3 days off in each 28-day cycle. Pomalidomide will be given at 4 mg once daily on days 1 through 21 of each cycle, and dexamethasone at 40 mg on days 1, 8, 15, and 22. Treatment will continue until disease progression, unacceptable side effects, or other withdrawal criteria are met. Approximately 100 patients will receive this combination treatment. During the study, participants will undergo regular assessments to evaluate treatment response based on International Myeloma Working Group criteria, including objective response rate measured by an independent review committee. Additional outcomes include duration and time to response, survival rates, and monitoring of any adverse events. Assessments will continue until disease progression or up to 48 months from enrollment, with safety monitored 28 days after treatment ends.

Age: 18Years +All GendersPhase 2
31 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of puxitatug samrotecan compared to a physicians choice of chemotherapy doxorubicin or paclitaxel in adults with advanced or metastatic endometrial cancer that has progressed after platinum-based chemotherapy and anti-PD-1anti-PD-L1 therapy. This Phase III, randomized, open-label study focuses on participants selected for B7-H4 expression and who have received no more than two prior treatments for advanced disease. Participants will be randomly assigned to receive either puxitatug samrotecan intravenously every three weeks or chemotherapy chosen by their physician. Chemotherapy options include doxorubicin given intravenously every three weeks or paclitaxel administered intravenously on days 1, 8, and 15 in a 28-day cycle. The study plans to enroll about 700 participants worldwide and compare how long participants live without cancer progression and overall survival between the two groups. During the study, participants will have regular assessments of their cancer status and quality of life. These will include imaging scans to measure tumor response and tracking of symptoms and side effects. Researchers will monitor progression-free survival, overall survival, response rates, duration of response, and time until further treatments are needed. The study will last approximately three years for outcome assessment, with safety and quality of life monitored throughout.

Age: 18Years +FEMALEPhase 3
320 locations
P

Actively Recruiting

Researchers are studying CCS1477 inobrodib to evaluate its safety, tolerability, pharmacokinetics, and biological activity in adults with advanced blood cancers, including Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Peripheral T-cell lymphoma, and High Risk Myelodysplastic Syndrome. This Phase 12a interventional trial aims to understand how CCS1477 works alone and in combination with other drugs in these conditions. Participants receive CCS1477 as an oral capsule, either alone or combined with other medications such as lenalidomide, pomalidomide-dexamethasone, bortezomib-dexamethasone, ixazomib-dexamethasone, elranatamab, teclistamab, daratumumab, azacitidine, and venetoclax. Treatment involves dose escalation and expansion phases with various combinations tailored to specific types of blood cancers. The study is non-randomized and sequential, with participants assigned to different arms based on their disease and treatment combinations. Throughout the study, participants undergo regular assessments to monitor safety, including tracking treatment-related adverse events and laboratory abnormalities for up to 12 months. Researchers also measure response rates, duration of response, and pharmacokinetic parameters such as drug exposure over 35 days. The study involves ongoing monitoring during and after treatment to evaluate the effects of CCS1477 and its combinations in these hematological malignancies.

Age: 18Years +All GendersPhase 1Phase 2
39 locations